SAH1 Antibody
Description
Introduction to SAH1 Antibody
SAH1 antibodies are immunoglobulins specifically designed to recognize and bind to S-Adenosylhomocysteine hydrolase (SAH1), an enzyme that plays a critical role in cellular metabolism. In yeast, this enzyme is referred to as Sah1, while in mammals it is known as AHCY . These antibodies serve as essential research tools for studying the expression, localization, and function of SAH1/AHCY in various biological contexts.
The significance of SAH1 antibodies stems from the central role of their target enzyme in methylation metabolism. S-Adenosylhomocysteine hydrolase is the sole enzyme responsible for the degradation of S-adenosyl-L-homocysteine (AdoHcy) to adenosine and homocysteine . This reaction is critical because AdoHcy is a potent inhibitor of S-adenosyl-L-methionine (AdoMet)-dependent methyltransferases, enzymes that catalyze essential methylation reactions in the cell .
Structure and Classification of SAH1 Antibodies
SAH1 antibodies, like other immunoglobulins, can be classified into different categories based on their structure and production method. They belong to one of the five primary classes of immunoglobulins: IgG, IgM, IgA, IgD, or IgE, with most research antibodies falling into the IgG class .
Types of SAH1 Antibodies
SAH1 antibodies are produced in two primary forms:
-
Monoclonal SAH1 Antibodies: These are derived from a single B lymphocyte clone, producing antibodies with identical specificity that recognize a single epitope on the SAH1 protein. An example is the Anti-SAH Antibody clone 301-1, which is a mouse monoclonal antibody specific to S-Adenosylhomocysteine .
-
Polyclonal SAH1 Antibodies: These contain a heterogeneous mixture of antibodies that recognize various epitopes on the SAH1 protein, produced by different B lymphocyte clones . Polyclonal antibodies offer broader reactivity but potentially less specificity compared to monoclonal counterparts.
Target Enzyme: SAH1/AHCY
To understand SAH1 antibodies, it is essential to comprehend their target enzyme and its biological significance.
Biochemical Function and Pathway
S-Adenosyl-L-homocysteine hydrolase (Sah1 in yeast/AHCY in mammals) plays a critical role in the methylation cycle. It catalyzes the reversible hydrolysis of S-adenosyl-L-homocysteine (AdoHcy) to adenosine and homocysteine . This reaction is crucial for several reasons:
-
It removes AdoHcy, which is a potent product inhibitor of AdoMet-dependent methyltransferases .
-
It provides homocysteine for the synthesis of cysteine/glutathione or remethylation to methionine/AdoMet .
-
In mammals, it constitutes the sole pathway for the synthesis of homocysteine, which is typically absent from the diet .
Structure and Conservation
The SAH1/AHCY enzyme is highly conserved across species, with variations in sequence but preservation of key functional domains. In yeast such as Saccharomyces cerevisiae and Candida albicans, the enzyme is referred to as Sah1, while in mammals, it is known as AHCY . The amino acid sequence of SAH1 in Candida albicans (strain SC5314) comprises 450 amino acids, as detailed in the recombinant protein information .
Role in Metabolism and Pathology
Research has demonstrated that SAH1/AHCY plays significant roles in lipid metabolism. Studies in yeast models have shown that:
-
Deletion of the SAH1 gene results in drastically reduced growth .
-
Downregulation of SAH1 expression leads to accumulation of AdoHcy and triglycerides (TG) in yeast .
-
Elevated homocysteine levels (hyperhomocysteinemia) lead to AdoHcy accumulation and subsequent deregulation of lipid metabolism .
These findings highlight the importance of SAH1 in cellular metabolism and suggest that dysregulation of this enzyme could contribute to metabolic disorders in humans.
Production Methods for SAH1 Antibodies
The production of high-quality SAH1 antibodies involves several sophisticated methods, each with distinct advantages and limitations.
Hybridoma Technology
Monoclonal SAH1 antibodies are typically produced using hybridoma technology, which involves the following steps:
-
Immunization of animals (commonly mice) with SAH1 protein or peptide conjugated to carrier proteins .
-
Isolation of B lymphocytes from the spleen or lymph nodes of immunized animals .
-
Fusion of isolated B lymphocytes with myeloma cells to create immortal hybridoma cell lines .
-
Screening and selection of hybridoma clones that produce SAH1-specific antibodies .
Recent advances in hybridoma screening have improved the efficiency of obtaining conformation-specific antibodies, such as the membrane-type immunoglobulin-directed hybridoma screening (MIHS) method and streptavidin-anchored ELISA screening technology (SAST) .
Recombinant Antibody Production
Recombinant DNA technology allows the production of SAH1 antibodies with defined properties:
-
Cloning of genes encoding the variable regions of SAH1-specific antibodies.
-
Expression of these genes in suitable host systems, such as mammalian cells, bacteria, or yeast.
-
Purification of the expressed antibodies using affinity chromatography.
This approach enables the generation of antibodies with modified properties, such as humanized antibodies, bispecific antibodies, or antibody fragments .
Polyclonal Antibody Production
Polyclonal SAH1 antibodies are generated by:
-
Immunizing animals (typically rabbits, goats, or sheep) with SAH1 protein or peptide conjugates .
-
Purifying SAH1-specific antibodies from the serum using affinity chromatography.
Applications of SAH1 Antibodies in Research
SAH1 antibodies serve as valuable tools in various research applications, providing insights into the expression, localization, and function of SAH1/AHCY.
Immunodetection Techniques
SAH1 antibodies are widely used in several immunodetection techniques:
-
Western Blotting: For detecting and quantifying SAH1 protein in cell or tissue lysates. For example, Anti-SAH Antibody [301-1] can be used at dilutions of 0.04-0.4 μg/mL for Western blotting .
-
Immunohistochemistry (IHC): For visualizing the distribution and localization of SAH1 in tissue sections. Anti-SAH Antibody [301-1] can be used at dilutions of 1:200 for IHC applications .
-
Flow Cytometry (FC): For detecting SAH1 in individual cells and analyzing its expression in different cell populations. Anti-SAH Antibody [301-1] can be used at dilutions of 1:200 for FC applications .
-
ELISA (Enzyme-Linked Immunosorbent Assay): For quantitative measurement of SAH1 in solutions. Competitive ELISA (cELISA) using Anti-SAH Antibody [301-1] can be performed at dilutions of 1:4,000-1:8,000 .
Metabolic Research
SAH1 antibodies have been instrumental in studying the role of SAH1/AHCY in metabolic pathways:
-
Lipid Metabolism: Studies using SAH1 antibodies have helped elucidate the relationship between SAH1 activity, AdoHcy accumulation, and changes in lipid profiles, particularly triglyceride levels and fatty acid composition .
-
Methylation Pathways: SAH1 antibodies have facilitated research on the role of SAH1 in methylation reactions and the impact of its dysfunction on cellular methylation status .
-
Homocysteine Metabolism: Research utilizing SAH1 antibodies has contributed to understanding the role of SAH1 in homocysteine metabolism and the consequences of elevated homocysteine levels (hyperhomocysteinemia) .
Clinical Research and Potential Therapeutic Applications
SAH1 antibodies have applications in clinical research related to conditions associated with dysregulated methylation and homocysteine metabolism:
-
Cardiovascular Diseases: Investigation of the relationship between SAH1 activity, homocysteine levels, and cardiovascular pathologies.
-
Neurological Disorders: Studies on the potential role of SAH1 in neurological conditions associated with altered methylation patterns.
-
Developmental Abnormalities: Research on the importance of SAH1 in embryonic development, as evidenced by the embryonic lethality observed in mice with deletion of the AHCY gene .
Specificity and Cross-Reactivity
The specificity of SAH1 antibodies is a critical factor in their research applications. For example, the Anti-SAH Antibody [301-1] shows the following reactivity profile :
-
S-Adenosylhomocysteine: 100%
-
S-Adenosylmethionine: ~1.5%
-
Adenosine: < 1%
-
Homocysteine: < 1%
-
L-Cysteine: < 1%
-
Glutathione: < 1%
-
L-Cystathionine: < 1%
-
Methythioadenosine (MTA): < 5%
-
ADP (adenosine diphosphate): < 1%
-
ATP (adenosine triphosphate): < 1%
This specificity profile indicates that the antibody is highly selective for S-Adenosylhomocysteine, with minimal cross-reactivity to related compounds.
Research Findings with SAH1 Antibodies
Research using SAH1 antibodies has yielded significant findings regarding the role of SAH1/AHCY in cellular metabolism and disease pathogenesis.
SAH1 and Lipid Metabolism
Studies employing SAH1 antibodies have revealed important relationships between SAH1 activity and lipid metabolism:
-
Triglyceride Accumulation: Experiments in yeast models have shown that downregulation of SAH1 expression or elevated homocysteine levels lead to accumulation of triglycerides, suggesting a role for SAH1 in lipid homeostasis .
-
Fatty Acid Composition: Research has demonstrated that changes in SAH1 activity affect not only the total content of fatty acids but also their composition, with notable alterations in the proportions of different fatty acid species .
-
Regulation of Lipid Synthesis Enzymes: Studies using SAH1 antibodies have shown that AdoHcy accumulation, resulting from reduced SAH1 activity, affects the activity and expression of enzymes involved in fatty acid synthesis and elongation, such as fatty acid synthase (FAS) and condensing enzymes of the fatty acid elongation complex .
SAH1 and Methylation Pathways
SAH1 antibodies have contributed to our understanding of the role of SAH1 in cellular methylation reactions:
-
Methyltransferase Inhibition: Research has confirmed that accumulation of AdoHcy due to reduced SAH1 activity inhibits AdoMet-dependent methyltransferases, affecting various methylation-dependent processes in the cell .
-
Alternative Pathways: Studies have explored alternative pathways for AdoHcy catabolism, such as the bacterial two-step pathway involving S-adenosylhomocysteine nucleosidase (Pfs) and S-ribosylhomocysteine lyase (LuxS), and their potential to complement SAH1 deficiency .
SAH1 in Disease Models
SAH1 antibodies have been used to investigate the potential role of SAH1/AHCY in various disease models:
-
Growth Defects: Research in yeast models has shown that deletion of the SAH1 gene results in significantly reduced growth, highlighting the essential nature of this enzyme .
-
Metabolic Disorders: Studies have examined the relationship between SAH1 activity, homocysteine levels, and metabolic alterations, providing insights into conditions such as hyperhomocysteinemia .
-
Embryonic Development: Research has demonstrated that deletion of the AHCY gene in mice leads to embryonic lethality, underscoring the critical role of this enzyme in development .
Future Directions in SAH1 Antibody Research
The field of SAH1 antibody research continues to evolve, with several promising directions for future investigation.
Improved Antibody Development Techniques
Advances in antibody engineering and screening technologies offer opportunities to develop SAH1 antibodies with enhanced specificity, affinity, and functionality:
-
Novel Screening Methods: The development of techniques such as the membrane-type immunoglobulin-directed hybridoma screening (MIHS) method and streptavidin-anchored ELISA screening technology (SAST) provide more efficient approaches for obtaining conformation-specific antibodies .
-
Bispecific Antibodies: The emerging field of bispecific antibodies, which can simultaneously bind two different antigens or epitopes, opens possibilities for developing SAH1 antibodies with dual specificity or enhanced functionality .
-
Single-Domain Antibodies: Research on single-domain antibodies (sdAbs), which comprise only the variable domains of heavy chain-only antibodies, may lead to the development of smaller SAH1 antibodies with unique binding properties and improved tissue penetration .
Expanded Clinical Applications
Future research may explore the potential clinical applications of SAH1 antibodies:
-
Diagnostic Tools: Development of SAH1 antibody-based diagnostic assays for conditions associated with altered SAH1 activity or homocysteine metabolism.
-
Therapeutic Strategies: Investigation of potential therapeutic applications targeting SAH1/AHCY or related pathways for metabolic disorders.
-
Personalized Medicine: Exploration of SAH1 activity as a biomarker for predicting individual responses to treatments for conditions related to methylation metabolism.
Integrative Research Approaches
Future studies may adopt integrative approaches combining SAH1 antibodies with other research tools:
-
Multi-Omics Integration: Combining SAH1 antibody-based studies with genomics, transcriptomics, proteomics, and metabolomics analyses to gain comprehensive insights into the role of SAH1 in cellular metabolism.
-
Structural Biology: Integration of SAH1 antibody research with structural studies of the SAH1/AHCY enzyme, potentially using antibodies as tools for crystallization or structure determination.
-
Systems Biology: Incorporation of SAH1 research into systems-level analyses of metabolic networks, providing a broader context for understanding the role of this enzyme in cellular homeostasis.
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
KEGG: sce:YER043C
STRING: 4932.YER043C
Q&A
What is the proper approach to validate antibodies for research applications?
Antibody validation requires a systematic, application-specific approach. The consensus among experts is that each antibody must be verified based on:
-
Content of the product datasheet
-
Experimental confirmation of specificity, selectivity, and integrity
-
Validation specific to the precise application and tissue/cell type
-
Open reporting of all verification data
The gold standard for validation includes:
-
Testing in knockout/knockdown models
-
Using multiple antibodies to different epitopes
-
Correlation with orthogonal methods (e.g., mRNA levels)
Research from The Antibody Society shows that despite various proposed validation solutions, these must be applied on a case-by-case basis, as no single approach is universally applicable .
In a large-scale study of 614 commercial antibodies against 65 neuroscience-related proteins, researchers found that:
This study revealed that while 50-75% of proteins had at least one high-performing antibody available (depending on application), more than 50% of all tested antibodies failed in one or more applications .
What essential controls should be included in antibody-based experiments?
Proper controls are critical for ensuring the reliability of antibody-based experiments:
Positive controls:
-
Cell lines with documented high expression of the target protein
-
Recombinant protein standards
-
Samples with known positivity
Negative controls:
-
Knockout/knockdown cell lines (gold standard)
-
Secondary antibody-only controls
-
Isotype controls
-
Samples known to lack the target protein
The YCharOS study demonstrated that knockout cell lines are superior to other types of controls, particularly for Western blotting and immunofluorescence applications .
For immunoprecipitation experiments, additional controls include:
-
Non-specific IgG pulldown controls
-
Pre-immune serum controls (for polyclonal antibodies)
How do different antibody types (monoclonal, polyclonal, recombinant) compare in research applications?
Each antibody type has distinct characteristics that affect its performance:
| Antibody Type | Characteristics | Best Applications | Limitations |
|---|---|---|---|
| Polyclonal | Heterogeneous mixture targeting multiple epitopes | Good signal amplification, robust to epitope changes | Batch-to-batch variability, potential cross-reactivity |
| Monoclonal | Single epitope specificity, consistent | Highly specific applications, reproducible results | May be sensitive to epitope modifications, potentially weaker signal |
| Recombinant | Sequence-defined, synthetically produced | Consistent performance, no batch variation, engineerable | Generally higher cost, may have specific expression system requirements |
Recent systematic comparisons show that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies across applications. In a comprehensive study of 614 antibodies, recombinant antibodies demonstrated superior consistency and specificity .
The key advantage of recombinant antibodies is their sequence-level definition, which guarantees production of a truly monoclonal antibody with no batch-to-batch variation .
What factors affect antibody specificity and how can they be mitigated?
Multiple factors can compromise antibody specificity:
-
Denatured antigens on beads/surfaces:
-
Antibody concentration/dilution:
-
Prozone effect:
-
Cross-reactivity:
Validation studies show that tissue/cell-specific expression patterns can dramatically affect antibody performance, requiring application-specific and context-specific validation protocols .
How can researchers address the prozone effect in antibody testing?
The prozone effect is a technical limitation that causes false-negative results in antibody testing due to extremely high antibody titers. Research has identified several effective approaches:
-
EDTA treatment:
-
Alternate treatments:
A study on HLA antibody detection found that only beads showing a prozone effect were covered with C1q, confirming the mechanism of interference. The researchers concluded:
"Addition of EDTA to serum of highly immunized patients is the easiest way to avoid false-negative results in SAB testing caused by a prozone effect."
This approach is particularly important in transplantation medicine where accurate antibody detection is critical for organ allocation decisions.
How can principal component analysis (PCA) be applied to improve antibody testing and interpretation?
Principal component analysis offers powerful tools for antibody data analysis:
-
Identification of abnormal antibody patterns:
-
Detection of overreactive beads:
A 2023 study demonstrated that PCA-derived analysis has "excellent negative predictive value and adequate positive predictive value" for identifying patient samples with abnormal HLA antibody reactivity patterns .
Implementation advantages include:
-
Decreased sample turnaround time
-
Simplified analysis for laboratory staff
-
Automated identification of significant changes in antibody profiles
What experimental designs are most appropriate for evaluating therapeutic antibody effectiveness?
For evaluating therapeutic antibody effectiveness, several experimental designs provide different levels of evidence quality:
True Experimental Designs:
These designs require:
Quasi-experimental Designs (when randomization isn't possible):
This approach is particularly suited for monitoring antibody effects over time .
A case study using the human monoclonal anti-endotoxin antibody HA-1A demonstrates effective experimental design in clinical settings. The study:
-
Randomly allocated 82 septic patients to receive HA-1A or placebo
-
Measured pretreatment endotoxemia
-
Found significant reduction in mortality in the HA-1A group (31% vs 73%, P=0.02)
-
Demonstrated a median decrease in serum TNF levels of 12 ng/L vs 0 ng/L (P=0.04)
How should researchers address contradictory results between different antibody-based techniques?
Contradictory results between techniques are common challenges requiring systematic troubleshooting:
-
Understand application-specific considerations:
-
Methodological approach to contradictions:
-
Reconciliation strategies:
The large-scale antibody validation study demonstrated that the correlation between antibody performance in different applications was relatively poor, with success in one application not necessarily predicting success in another. This finding highlights the importance of application-specific validation .
What factors contribute to batch-to-batch variability in antibodies and how can this be managed?
Batch-to-batch variability represents a significant challenge in antibody research:
Contributing factors:
-
Production method:
-
Storage and handling:
-
Freeze-thaw cycles
-
Improper temperature
-
Buffer conditions
-
Management strategies:
-
Documentation:
-
Pre-emptive testing:
-
Test new batches against old batches before using in critical experiments
-
Maintain internal standards/positive controls
-
-
Transition to recombinant antibodies:
-
Validation protocols:
What are the current standards for antibody validation in high-impact publications?
Current standards for antibody validation in high-impact publications include:
-
Tiered validation approach:
-
International Working Group for Antibody Validation (IWGAV) recommendations:
-
Journal-specific requirements:
The benchmark for validation is increasingly focused on knockout/knockdown controls. A recent study of 614 antibodies found that using knockout cell lines was superior to other validation methods, particularly for Western blotting and immunofluorescence applications .
How are recombinant antibody technologies changing the landscape of antibody research?
Recombinant antibody technologies are revolutionizing antibody research through:
-
Sequence-defined production:
-
Structural design improvements:
-
Performance advantages:
A comprehensive survey of 50 distinct synthetic antibody-antigen complexes found that:
-
Despite minimalist design strategies, synthetic antibodies achieve molecular recognition similar to natural antibodies
-
Key structural differences offer opportunities for iterative improvement
-
Positionally tailored diversity can enhance binding properties
The data demonstrates that recombinant antibodies outperformed both monoclonal and polyclonal antibodies in systematic testing, suggesting they will play an increasingly important role in research antibody applications .
What new methodologies are being developed to address the challenges of antibody validation?
Several innovative approaches are emerging to address antibody validation challenges:
-
Centralized third-party validation:
-
Knockout cell collections:
-
Machine learning applications:
-
Multi-parameter validation:
The YCharOS initiative demonstrates the impact of independent validation, identifying hundreds of underperforming antibodies that had been used in published research. This led to manufacturers removing 73 antibodies from the market and changing recommendations for 153 others, highlighting the value of systematic third-party testing .
